EC Gynaecology

One of the gynecological cancers with the highest female fatality rate worldwide is ovarian cancer. The extremely high heterogeneity of the illness, its resistance to platinum-based chemotherapy, and the difficulties in performing surgery can be blamed for the modest drop in ovarian cancer mortality. Furthermore, there is no reliable ovarian cancer screening method. Numerous studies, particularly those on micro-RNA, have considerably advanced our understanding of the pathophysiology of ovarian cancer at the molecular level. Short, single-stranded, highly conserved non-coding RNA molecules are known as micro-RNAs (miRNAs) (19 - 25 nucleotides). Numerous studies have found that ovarian cancer and ovarian cancer cell lines exhibit either increased or decreased miRNA expression. The next step is to gather this data and use it to create medicines that target miRNA in order to manage ovarian cancer effectively. This review sought to compile all anti-miRNA investigations that had been done in opposition to miRNA overexpression in ovarian cancer.

Keywords: Ovarian Cancer; Ovarian Malignancy; Ovarian Neoplasm; miRNA; Antagonist miRNA; Anti-miRNA

1. Sung H., et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal for Clinicians 71 (2021): 209-249.
2. Webb PM and Jordan SJ. “Epidemiology of epithelial ovarian cancer”. Best Practice and Research Clinical Obstetrics and Gynaecology 41 (2017): 3-14.
3. Ledermann JA., et al. “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up”. Annals of Oncology 24 (2013): vi24-32.
4. Bast RC., et al. “The biology of ovarian cancer: new opportunities for translation”. Nature Reviews Cancer 9 (2009): 415-428.
5. Feinbaum R., et al. “The C. elegans Heterochronic Gene lin-4 Encodes Small RNAs with Antisense Complementarity to lin-14”. Cell 116 (2004): 843-854.
6. Kinose Y., et al. “The Role of MicroRNAs in Ovarian Cancer”. BioMed Research International (2014): 2670-2767.
7. Alshamrani AA. “Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?” Frontiers in Oncology (2020): 10.
8. Hayes J., et al. “MicroRNAs in cancer: Biomarkers, functions and therapy”. Trends in Molecular Medicine 20 (2014): 460-469.
9. Hammond SM. “An overview of microRNAs”. Advanced Drug Delivery Reviews 87 (2015): 3-14.
10. Iorio MV., et al. “MicroRNA signatures in human ovarian cancer”. Cancer Research 67 (2007): 8699-8707.
11. Kozomara A and Griffiths-Jones S. “MiRBase: Annotating high confidence microRNAs using deep sequencing data”. Nucleic Acids Research 42 (2014): 68-73.
12. Roden C., et al. “Novel determinants of mammalian primary microRNA processing revealed by systematic evaluation of hairpin-containing transcripts and human genetic variation”. Genome Research 27 (2017): 374-384.
13. Chen SN., et al. “MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities”. International Journal of Environmental Research and Public Health 16 (2016): 1-14.
14. Ha M and Kim VN. “Regulation of microRNA biogenesis”. Nature Reviews Molecular Cell Biology 15 (2014): 509-524.
15. Blahna M and Akiko H. “Regulation of miRNA biogenesis as an integrated component of growth factor signaling”. Current Opinion in Cell Biology 25 (2013): 233-240.
16. Resnick KE., et al. “The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform”. Gynecologic Oncology 112 (2009): 55-59.
17. Ruan K., et al. “MicroRNAs: Novel regulators in the hallmarks of human cancer”. Cancer Letters 285 (2009): 116-126.
18. Wagner EF and Nebreda ÁR. “Signal integration by JNK and p38 MAPK pathways in cancer development”. Nature Reviews Cancer 9 (2009): 537-549.
19. Kim EK and Choi EJ. “Pathological roles of MAPK signaling pathways in human diseases”. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1802 (2010): 396-405.
20. Liu N., et al. “Upregulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer”. Neoplasma 62 (2015): 550-559.
21. Shi C., et al. “Mir-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9”. OncoTargets and Therapy 12 (2019): 8329-8338.
22. Mak CSL., et al. “MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis”. Molecular Cancer 16 (2017): 1-17.
23. Chen J., et al. “Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells”. Gynecologic Oncology 121 (2011): 200-205.
24. Koutsaki M., et al. “The miR-200 family in ovarian cancer”. Oncotarget 8 (2017): 66629-66640.
25. Zhang S., et al. “MiR-630 promotes epithelial ovarian cancer proliferation and invasion via targeting KLF6”. European Review for Medical and Pharmacological Sciences 21 (2017): 4542-4547.
26. Shell S., et al. “Let-7 expression defines two differentiation stages of cancer”. Proceedings of the National Academy of Sciences of the United States of America 104 (2007): 11400-11405.
27. Wu J., et al. “HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes”. Cancer Research 71 (2011): 349-359.
28. Liu G., et al. “MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer”. The Journal of Pathology 233 (2014): 308-318.
29. Xia B., et al. “miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6”. Molecular Cancer 14 (2015): 1-13.
30. Yan J., et al. “MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression”. Journal of Experimental and Clinical Cancer Research 35 (2016): 1-10.
31. Al-Shihabi A., et al. “Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy”. Molecular Therapy Oncolytics 11 (2018): 122-126.
32. Salem M., et al. “miR-590-3p targets cyclin G2 and FOXO3 to promote ovarian cancer cell proliferation, invasion, and spheroid formation”. International Journal of Molecular Sciences (2019): 20.
33. Lima JF., et al. “Anti-miRNA oligonucleotides: A comprehensive guide for design”. RNA Biology 15 (2018): 338-352.
34. Wang Z. “The Guideline of the Design and Validation of MiRNA Mimics BT - MicroRNA and Cancer: Methods and Protocols”. MicroRNA and Cancer 676 (2011): 211-223.
35. Chan JK., et al. “The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer”. Gynecologic Oncology 132 (2014): 739-744.
36. Mahmoud EH., et al. “Serum microRNA-21 negatively relates to expression of programmed cell death-4 in patients with Epithelial ovarian cancer”. Asian Pacific Journal of Cancer Prevention 19 (2018): 33-38.
37. Vandghanooni S., et al. “AS1411 aptamer-decorated cisplatin-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells”. Nanomedicine (2018): 13.
38. Liu Y., et al. “Ultrasound-Mediated Long-Circulating Nanopolymer Delivery of Therapeutic siRNA and Antisense MicroRNAs Leads to Enhanced Paclitaxel Sensitivity in Epithelial Ovarian Cancer Chemotherapy”. ACS Biomaterials Science and Engineering 6 (2020): 4036-4050.
39. Bertucci A., et al. “Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy”. ACS Applied Materials and Interfaces 11 (2019): 23926-23937.
40. Javanmardi S., et al. “Redox-sensitive, PEG-shielded carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes resistant ovarian cancer cells to cisplatin”. Asian Journal of Pharmaceutics 15 (2020): 69-82.
41. Raniolo S., et al. “Combined and selective miR-21 silencing and doxorubicin delivery in cancer cells using tailored DNA nanostructures”. Cell Death and Disease 12 (2021): 3-11.
42. Frenzel A., et al. “Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad”. Blood 115 (2010): 995-1005.
43. Kutuk O and Letai A. “Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells”. Cell Death and Differentiation 17 (2010): 1624-1635.
44. Wang R., et al. “Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer”. Cancer Letters 381 (2016): 341-348.
45. Zhang K-C., et al. “Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis”. American Journal of Cancer Research 5 (2015): 821-829.
46. Yang H., et al. “MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN”. Cancer Research 68 (2008): 425-433.
47. Wang X., et al. “Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer”. Molecular Therapy 26 (2018): 774-783.
48. Vandghanooni S., et al. “Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells”. International Journal of Pharmaceutics 573 (2020): 118729.
49. Li T., et al. “Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer”. American Journal of Cancer Research 11 (2021): 2124-2141.
50. Jin AH and Wei ZL. “Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression”. International Journal of Clinical and Experimental Medicine 8 (2015): 13329-13334.
51. Xu L., et al. “Prognostic significance of several biomarkers in epithelial ovarian cancer: A meta-analysis of published studies”. Journal of Cancer Research and Clinical Oncology 139 (2013): 1257-1277.
52. Chen X., et al. “Identifying and targeting angiogenesis-related microRNAs in ovarian cancer”. Oncogene 38 (2019): 6095-6108.
53. Gong J., et al. “Circular RNA-9119 suppresses in ovarian cancer cell viability via targeting the microRNA-21-5p-PTEN-Akt pathway”. Aging (Albany NY) 12 (2020): 14314-14328.
54. Zhang X Yan., et al. “Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis”. Scientific Reports 10 (2020): 1-8.
55. Xie X., et al. “miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF”. Oncology Letters 16 (2018): 6697-6704.
56. Suardi RB., et al. “The effects of combination of mimic miR-155-5p and antagonist miR-324-5p encapsulated chitosan in ovarian cancer SKOV3”. Asian Pacific Journal of Cancer Prevention 21 (2020): 2603-2608.
57. Liu J., et al. “Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene”. Biomedicine and Pharmacotherapy 83 (2016): 1286-1294.
58. Tsuda N., et al. “Synthetic microRNA and double-stranded RNA targeting the 3′-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells”. International Journal of Oncology 27 (2005): 1299-1306.
59. He S-L., et al. “CircAHNAK upregulates EIF2B5 expression to inhibit the progression of ovarian cancer by modulating the JAK2/STAT3 signaling pathway”. Carcinogenesis (2022).
60. Liu M., et al. “Long Noncoding RNA LINC01133 Confers Tumor-Suppressive Functions in Ovarian Cancer by Regulating Leucine-Rich Repeat Kinase 2 as an miR-205 Sponge”. The American Journal of Pathology 189 (2019): 2323-2339.
61. Zhu W., et al. “Silencing of the long noncoding RNA LINC01132 alleviates the oncogenicity of epithelial ovarian cancer by regulating the microRNA-431-5p/SOX9 axis”. International Journal of Molecular Medicine (2021): 48.
62. Guo R and Qin Y. “LEMD1-AS1 suppresses ovarian cancer progression through regulating MiR-183-5p/tp53 axis”. OncoTargets and Therapy 13 (2020): 7387-7398.
63. Chang H., et al. “MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis”. Cancer Medicine 9 (2020): 6377-6386.
64. Liu Y., et al. “LncRNA MEG3 suppressed the progression of ovarian cancer via sponging miR-30e-3p and regulating LAMA4 expression”. Cancer Cell International 20 (2020): 1-15.
65. Zhang Y., et al. “Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1”. Biological Research 53 (2020): 1-10.
66. Miao S., et al. “LncRNA TTN-AS1 acts as sponge for miR-15b-5p to regulate FBXW7 expression in ovarian cancer”. Bio Factors 46 (2020): 600-607.
67. Horita K., et al. “Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer”. Biochemical and Biophysical Research Communications 516 (2019): 831-838.
68. Li X., et al. “CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228/ p53/epithelial-mesenchymal transition (EMT) axis”. Journal of Cancer 11 (2020): 599-609.
69. Ye W., et al. “Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA‑Meg3/miR‑421/PDGFRA axis”. International Journal of Oncology 55 (2019): 1296-1
70. Xue CL., et al. “Physcion 8-O-β-glucopyranoside exhibits anti-growth and anti-metastatic activities in ovarian cancer by downregulating miR-25”. European Review for Medical and Pharmacological Sciences 23 (2019): 5101-5112.
71. Gokulnath P., et al. “Long non-coding RNA HAND2-AS1 acts as a tumor suppressor in high-grade serous ovarian carcinoma”. International Journal of Molecular Sciences 21 (2020): 1-16.
72. Zhou X., et al. “Hsa_circ_0004712 downregulation attenuates ovarian cancer malignant development by targeting the miR-331-3p/FZD4 pathway”. Journal of Ovarian Research (2021): 14.
73. Lian J., et al. “Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1”. Cell Death and Disease 1 (2010): 1-12.
74. Luo H., et al. “Down-regulated miR-9 and miR-433 in human gastric carcinoma”. Journal of Experimental and Clinical Cancer Research 28 (2009): 1-9.
75. He Z., et al. “Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor”. Medical Oncology 30 (2013): 0-5.
76. Li KKW., et al. “MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3)”. Brain Pathology 23 (2013): 413-425.
77. Yin M., et al. “Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1”. Molecular Endocrinology 26 (2012): 1129-1143.
78. Rooij E and Kauppinen S. “Development of micro RNA therapeutics is coming of age”. EMBO Molecular Medicine 6 (2014): 851-864.
79. Van Der Ree MH., et al. “Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients”. Antiviral Research 111 (2014): 53-59.
80. Van Der Ree MH., et al. “Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial”. Lancet 389 (2017): 709-717.
81. Collison AM., et al. “miR-122 promotes virus-induced lung disease by targeting SOCS1”. JCI Insight 6 (2021): 1-8.
82. Abplanalp WT., et al. “Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study”. Nucleic Acid Therapeutics 30 (2020): 335-345.